Bsher Touleimat, MD
Pulmonary Disease · Harvey, ILNPI 1588640049
Payments from drug & device makers
Across 103 payments — averaging $39.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- AstraZeneca$755
- Verathon Inc.$595
- Boehringer Ingelheim$538
- Jazz Pharmaceuticals Inc.$211
- Genentech USA, Inc.$111
- plus $784 from 16 others
What the payments were for
- Consulting fees$1,05526%
- Speaking & faculty fees$1002%
- Food & beverage$2,84970%
- Education$902%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 42 | $1,100 |
| AstraZeneca | 14 | $755 |
| Verathon Inc. | 1 | $595 |
| Boehringer Ingelheim | 10 | $538 |
| Jazz Pharmaceuticals Inc. | 5 | $211 |
| Genentech USA, Inc. | 1 | $111 |
| United Therapeutics Corporation | 1 | $100 |
| Mallinckrodt Hospital Products Inc. | 3 | $91 |
| Sanofi | 4 | $90 |
| Philips North America LLC | 3 | $73 |
| Pulmonx Corporation | 1 | $62 |
| Verona Pharma, Inc. | 3 | $58 |
| Inogen, Inc. | 2 | $45 |
| Medtronic | 1 | $45 |
| Insmed, Inc. | 2 | $35 |
| Novartis | 1 | $35 |
| Regeneron Healthcare Solutions, Inc. | 1 | $34 |
| Electromed, Inc. | 3 | $34 |
| Mylan Specialty L.p. | 2 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Baxter Healthcare | 1 | $15 |
| Actelion Pharmaceuticals US, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,094 in reported general payments places this provider in the 60th percentile of 539 pulmonary disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 31 | $410,626 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 221 | $176,701 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 100 | $75,750 |
| Spiriva RespimatTiotropium Bromide | 59 | $53,741 |
| EliquisApixaban | 55 | $41,573 |
| Breo ElliptaFluticasone/Vilanterol | 68 | $26,078 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 83 | $22,938 |
| SymbicortBudesonide/Formoterol Fumarate | 74 | $21,881 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 36 | $16,951 |
| Incruse ElliptaUmeclidinium Bromide | 33 | $15,360 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 24 | $12,691 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 333 | $10,154 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 36 | $7,882 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 15 | $6,546 |
| Arnuity ElliptaFluticasone Furoate | 15 | $5,036 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat | $538 | $477,058114 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $1,100 | $240,126373 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $755 | $104,177189 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 539 pulmonary disease providers in Illinois.
Other pulmonary disease in Harvey
- Douglas HogarthChicago$3.1M
- Manu JainChicago$1.9M
- Momen WahidiChicago$1.2M
- Shashi BellamEvanston$1.2M
- Marilyn GlassbergMaywood$1000K
- Steven WhiteChicago$989K
- Ravi KalhanChicago$831K
- Patrick WhittenPeoria$812K
- Jane Dematte DamicoChicago$811K
- Septimiu MurguChicago$804K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.